$HLF

Herbalife’s (NYSE:HLF) Q3 2026 sales beat estimates, stock soars

Herbalife (HLF) reported Q3 2026 revenue of $1.35B, beating estimates by 3.2%, and adjusted EPS of $0.64, exceeding expectations by 3.7%. Adjusted EBITDA was $182.4M, a 7.9% beat. Q4 revenue guidance is $1.32B, in line with estimates, while full-year EBITDA guidance is $680M, above consensus. Operating and free cash flow margins remained steady year-over-year.

Original reporting
Published Nov 2, 2026, 10:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 10:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Herbalife’s (NYSE:HLF) Q3 2026 sales beat estimates, stock soars — source image
Decision brief

The 30-second read

$HLFBullishHigh
01

Why it matters

The earnings beat and modestly positive guidance are likely to sustain short‑term upside.

02

Market read

Earnings beat provides a clear catalyst for traders; the stock's rally reflects immediate market reaction.

03

What to watch

Potential supply‑chain cost pressures not reflected in guidance.

Relevance 9/10Novelty 9/10Timing: post-market today

Background

Herbalife is a global nutrition and weight‑loss company listed on NYSE.

Company-level read

Ticker impact

$HLFBullishHigh confidence
Context

Herbalife reported Q3 2026 revenue and EPS beats, prompting the stock to soar.

Expected impact

likely upward pressure as investors price in the beat and strong guidance.

Evidence & confidence

Revenue and EPS both exceeded consensus, and guidance is in line or slightly above expectations, supporting a rally.

Market effects

Weight loss and nutrition sector may see modest uplift from Herbalife's beat.

U.S. consumer discretionary sentiment boosted.

Limited to investors tracking mid‑cap earnings.

Counterpoint

Some analysts may question sustainability of growth given modest guidance.

Key entities

  • Herbalife Nutrition Ltd.

    Subject of the earnings report.

Related articles

$HLFMedAI 8/10

Herbalife Ltd (HLF) (Q3 2026) Earnings Call Highlights: Fifth Straight Quarter

Herbalife (HLF) reported Q3 2026 net sales of $1.4B, up 6% YoY, and adjusted EBITDA of $182M, beating guidance. Growth was driven by India and nutrition clubs, while EMEA and China saw declines. The company raised full-year sales guidance but expects gradual margin expansion. Interim CEO John DeSimone discussed product repositioning and new technology platforms. Operating cash flow rose 27% YoY, and net leverage improved to 2.0x.

$HLFHighAI 8/10

Why Herbalife Stock Is Up Today

Herbalife (HLF) shares rose 8% after Q3 results showed 6% revenue growth to $1.35B, with Asia Pacific up 18%. Adjusted net income increased 33% to $68.5M. The company raised full-year sales guidance and announced a $250M stock buyback program. According to interim CEO John DeSimone, growth is driven by 3M+ independent distributors.

$HLFMedAI 8/10

Herbalife Reports Q3 2026 Financial Results

Herbalife Ltd. reported Q3 2026 net sales of $1.35B, up 6% YoY, with regional growth varying. Adjusted EBITDA was $182.4M, EPS $0.55. Gross margin slightly declined to 77.3%. The company cited refinancing benefits and debt reduction. Management expects continued net sales growth.

$HLFHighAI 8/10

Herbalife (HLF) Q3 2026 Earnings Call Transcript

Herbalife (HLF) reported Q3 2026 net sales of $1.4B, up 6% YoY, and adjusted EBITDA of $182M, exceeding guidance. Interim CEO John DeSimone highlighted growth opportunities, including strengthening Nutrition Clubs and expanding the Bioniq brand. The company aims to enhance distributor support and technology capabilities.

$HLFMedAI 8/10

What Herbalife (HLF) Said on Its Q3 Earnings Call

Herbalife (HLF) reported Q3 sales growth of 5.1% in constant currency and 9% reported, with North America up 1.7%. FX reduced net sales by $21M. The company outlined priorities: nutrition clubs, tech platforms, and Bioniq brand growth. It expects Q4 sales growth of 0.5% to 4.5% and raised full-year sales guidance to 4.9% to 5.9%. Operating cash flow rose 27% YoY to $298M.